Lexiscan regadenoson: Phase IV data

A double-blind Phase IV trial in 999 patients with asthma (n=532) or chronic obstructive pulmonary disease (COPD) (n=467) who were likely candidates for MPI studies showed that 0.4 mg IV regadenoson met the primary endpoint of non-inferiority to placebo in the proportion of patients who experienced a >15% worsening in FEV1 at 2 hours post-dose (p=0.1451 for asthma patients and p=0.579 for COPD patients). Data were presented at the American Society of Nuclear Cardiology meeting in Philadelphia. ...